In mCRPC, eligibility for 177Lu-PSMA radionuclide therapy is based on a positive 68Ga-PSMA-PET scan defined as tumor/liver ratio >1, as is the case in the currently recruiting phase 3 trial (VISION, NCT03511664). This evidence concerns the gene FOLH1 and neoplasm.